VA Continues Research on Radioligands to Optimize Treatment of mCRPC

The promising outcomes from studies of the radioligand lutetium Lu 177 vipivotide tetraxetan (Lu177-PSMA) as a second-line therapy for metastatic castration-resistant prostate cancer (mCRPC) has encouraged researchers to explore its effectiveness when moved earlier in treatment and in combination with other cancer therapies.

Essien Pushes Pharmacoequity in VA Healthcare to Combat Disparities

Essien Pushes Pharmacoequity in VA Healthcare to Combat Disparities

A general internist and health services researcher with the Center for the Study of Healthcare Innovation, Implementation, and Policy (CSHIIP) at the Greater Los Angeles Healthcare System, Utibe Essien, MD, MPH, has devoted his career to defining and then breaking down the systemic problems that lead to healthcare inequity.